All In Biotech

Drug Trial Radar · NCT07449442

SII Levels Following iPACK Block With Adductor Canal Block in Knee Arthroplasty

iPACK Block With Adductor Canal Block Mitigates Surgical Stress and Enhances Analgesia in Total Knee Arthroplasty: A Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Mar 1, 2026

Primary completion

Nov 30, 2026

Study completion Dec 1, 2026

Sponsor

Lead sponsor
Poznan University of Medical SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 65 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized controlled trial evaluates the effect of ultrasound-guided iPACK block with Adductor Canal Block (ACB) on the Systemic Immune-Inflammation Index (SII) in elderly patients undergoing total hip arthroplasty under spinal anesthesia. SII, calculated as platelet × neutrophil / lymphocyte count, is used as a composite marker of perioperative inflammatory and immune response. The study investigates whether iPACK block with ACB attenuates the systemic inflammatory reaction to surgical trauma compared to sham block.

Conditions

  • Knee Osteoarthritis

Interventions

  • sodium ChlorideDrug

    After spinal anesthesia, the ultrasound-guided iPACK block will be performed with 20ml of 0.9% sodium chloride; and Adductor Canal Block will be performed with 20ml of 0.9% sodium chloride

  • Ropivacaine HydroclorideDrug

    After spinal anesthesia, the ultrasound-guided iPACK block will be performed with 20ml of 0.2% ropivacaine, and the Adductor Canal Block will be performed with 20ml of 0.2% ropivacaine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Systemic Inflammation Response Index (SIRI)Time frame: 12 hours after surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Poznan University of Medical Sciences

    Poznan, Poland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.